224 related articles for article (PubMed ID: 31467228)
1. Fusion of the Genes
Panagopoulos I; Gorunova L; Lund-Iversen M; Bassarova A; Heim S
Cancer Genomics Proteomics; 2019; 16(5):345-351. PubMed ID: 31467228
[TBL] [Abstract][Full Text] [Related]
2. Novel recurrent PHF1-TFE3 fusions in ossifying fibromyxoid tumors.
Suurmeijer AJH; Song W; Sung YS; Zhang L; Swanson D; Fletcher CDM; Dickson BC; Antonescu CR
Genes Chromosomes Cancer; 2019 Sep; 58(9):643-649. PubMed ID: 30920708
[TBL] [Abstract][Full Text] [Related]
3. A PHF1-TFE3 fusion atypical ossifying fibromyxoid tumor with prominent collagenous rosettes: Case report with a brief review.
Zou C; Ru GQ; Zhao M
Exp Mol Pathol; 2021 Dec; 123():104686. PubMed ID: 34560087
[TBL] [Abstract][Full Text] [Related]
4. Round cell tumor with a myxoid matrix harboring a PHF1-TFE3 fusion: Myoepithelial neoplasm or ossifying fibromyxoid tumor?
Fei F; Prieto Granada CN; Harada S; Siegal GP; Wei S
Pathol Res Pract; 2021 Sep; 225():153578. PubMed ID: 34391181
[TBL] [Abstract][Full Text] [Related]
5. Gene of the month: TFE 3.
Pinto K; Chetty R
J Clin Pathol; 2020 Nov; 73(11):691-694. PubMed ID: 32820043
[TBL] [Abstract][Full Text] [Related]
6. Superficial malignant ossifying fibromyxoid tumors harboring the rare and recently described ZC3H7B-BCOR and PHF1-TFE3 fusions.
Linos K; Kerr DA; Baker M; Wong S; Henderson E; Sumegi J; Bridge JA
J Cutan Pathol; 2020 Oct; 47(10):934-945. PubMed ID: 32352579
[TBL] [Abstract][Full Text] [Related]
7. Absence of TFE3 Immunoexpression in a Spectrum of Cutaneous Mixed Tumors: A Retrospective Pilot Study.
Zengin HB; Yildiz B; Pukhalskaya T; Smoller BR
Dermatopathology (Basel); 2022 Jan; 9(1):48-53. PubMed ID: 35225876
[TBL] [Abstract][Full Text] [Related]
8. The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25.
Ladanyi M; Lui MY; Antonescu CR; Krause-Boehm A; Meindl A; Argani P; Healey JH; Ueda T; Yoshikawa H; Meloni-Ehrig A; Sorensen PH; Mertens F; Mandahl N; van den Berghe H; Sciot R; Dal Cin P; Bridge J
Oncogene; 2001 Jan; 20(1):48-57. PubMed ID: 11244503
[TBL] [Abstract][Full Text] [Related]
9.
Panagopoulos I; Gorunova L; Andersen K; Lund-Iversen M; Lobmaier I; Micci F; Heim S
Cancer Genomics Proteomics; 2020; 17(3):237-248. PubMed ID: 32345665
[TBL] [Abstract][Full Text] [Related]
10. TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers.
Argani P; Zhong M; Reuter VE; Fallon JT; Epstein JI; Netto GJ; Antonescu CR
Am J Surg Pathol; 2016 Jun; 40(6):723-37. PubMed ID: 26975036
[TBL] [Abstract][Full Text] [Related]
11. A YAP1::TFE3 cutaneous low-grade fibromyxoid neoplasm: A novel entity!
Patton A; Bridge JA; Liebner D; Chung C; Iwenofu OH
Genes Chromosomes Cancer; 2022 Apr; 61(4):194-199. PubMed ID: 34874592
[TBL] [Abstract][Full Text] [Related]
12. PHF1 fusions cause distinct gene expression and chromatin accessibility profiles in ossifying fibromyxoid tumors and mesenchymal cells.
Hofvander J; Jo VY; Fletcher CDM; Puls F; Flucke U; Nilsson J; Magnusson L; Mertens F
Mod Pathol; 2020 Jul; 33(7):1331-1340. PubMed ID: 31932680
[TBL] [Abstract][Full Text] [Related]
13. Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents.
Argani P; Antonescu CR; Illei PB; Lui MY; Timmons CF; Newbury R; Reuter VE; Garvin AJ; Perez-Atayde AR; Fletcher JA; Beckwith JB; Bridge JA; Ladanyi M
Am J Pathol; 2001 Jul; 159(1):179-92. PubMed ID: 11438465
[TBL] [Abstract][Full Text] [Related]
14. SFPQ/PSF-TFE3 renal cell carcinoma: a clinicopathologic study emphasizing extended morphology and reviewing the differences between SFPQ-TFE3 RCC and the corresponding mesenchymal neoplasm despite an identical gene fusion.
Wang XT; Xia QY; Ni H; Ye SB; Li R; Wang X; Shi SS; Zhou XJ; Rao Q
Hum Pathol; 2017 May; 63():190-200. PubMed ID: 28315422
[TBL] [Abstract][Full Text] [Related]
15. Ossifying fibromyxoid tumor presenting EP400-PHF1 fusion gene.
Endo M; Kohashi K; Yamamoto H; Ishii T; Yoshida T; Matsunobu T; Iwamoto Y; Oda Y
Hum Pathol; 2013 Nov; 44(11):2603-8. PubMed ID: 23806526
[TBL] [Abstract][Full Text] [Related]
16. Validation and utilization of a TFE3 break-apart FISH assay for Xp11.2 translocation renal cell carcinoma and alveolar soft part sarcoma.
Pradhan D; Roy S; Quiroga-Garza G; Cieply K; Mahaffey AL; Bastacky S; Dhir R; Parwani AV
Diagn Pathol; 2015 Sep; 10():179. PubMed ID: 26415891
[TBL] [Abstract][Full Text] [Related]
17. Recurrent rearrangement of the PHF1 gene in ossifying fibromyxoid tumors.
Gebre-Medhin S; Nord KH; Möller E; Mandahl N; Magnusson L; Nilsson J; Jo VY; Vult von Steyern F; Brosjö O; Larsson O; Domanski HA; Sciot R; Debiec-Rychter M; Fletcher CD; Mertens F
Am J Pathol; 2012 Sep; 181(3):1069-77. PubMed ID: 22796436
[TBL] [Abstract][Full Text] [Related]
18. Novel ZC3H7B-BCOR, MEAF6-PHF1, and EPC1-PHF1 fusions in ossifying fibromyxoid tumors--molecular characterization shows genetic overlap with endometrial stromal sarcoma.
Antonescu CR; Sung YS; Chen CL; Zhang L; Chen HW; Singer S; Agaram NP; Sboner A; Fletcher CD
Genes Chromosomes Cancer; 2014 Feb; 53(2):183-93. PubMed ID: 24285434
[TBL] [Abstract][Full Text] [Related]
19. A novel partner of TFE3 in the Xp11 translocation renal cell carcinoma: clinicopathological analyses and detection of EWSR1-TFE3 fusion.
Fukuda H; Kato I; Furuya M; Tanaka R; Takagi T; Kondo T; Nagashima Y
Virchows Arch; 2019 Mar; 474(3):389-393. PubMed ID: 30552521
[TBL] [Abstract][Full Text] [Related]
20. Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay.
Argani P; Lal P; Hutchinson B; Lui MY; Reuter VE; Ladanyi M
Am J Surg Pathol; 2003 Jun; 27(6):750-61. PubMed ID: 12766578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
